Clinical Trial Update: 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating whether 18F-Fluciclovine PET/CT can predict outcomes of 177Lu-PSMA-617 therapy in prostate cancer patients. The study is currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Axumin (fluciclovine F-18)
• Pluvicto (lutetium-177 PSMA-617)

Snippet

Sponsor: VA Greater Los Angeles Healthcare System | Conditions: Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant | Phase 4 | Status: RECRUITING